Fabbiani M, Rossetti B, Ciccullo A, et al. - The efficacy and durability of treatment switching to two-drug (2DR) vs three-drug (3DR) integrase inhibitor (InSTI)-based regimens were investigated in a real-life setting. Within the ODOACRE cohort, researchers selected a total of 1,666 patients for inclusion. Of these patients, 1,334 (80%) received treatment with a 3DR regimen (19.9%, 25.0% and 55.1% elvitegravir-, raltegravir- and dolutegravir-based, respectively) and 332 (20%) with a 2DR (79.2% dolutegravir + lamivudine and 20.8% dolutegravir + rilpivirine) regimen. Per outcomes, 2DRs show an efficacy similar to 3DRs in virologically suppressed HIV-infected patients but with better tolerability.